PREX2 and neoplasm: Further evidence can be found in non-small-cell lung cancer, where CELF2 is capable of inhibiting tumor development by antagonizing PREX2 (Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 2)’s oncogenic impact and regulates PI3-K signaling [79].